Skip to Content



Conquest - Spring 2012

Latest research advances

Research discoveries made at MD Anderson are leading to improved therapies for cancer patients.

Here are some recent advances. Select any headline to read more about that topic.

The new Institute for Applied Cancer Science, led by Giulio Draetta, M.D., Ph.D., and Lynda Chin, M.D., is gearing up to develop better drugs faster.

Obese rhesus monkeys treated with an experimental drug that starves fat cells by destroying their blood supply lost, on average, 11% of their body weight in four weeks.

A promising oral drug for chronic lymphocytic leukemia has produced durable remissions for patients in clinical trials without triggering a debilitating side effect that's common with existing treatments.

Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85% remission rate after initial treatment.

A large-scale analysis of patients whose myelodysplastic syndrome is related to earlier cancer treatment overturns the notion that all of them have a poor prognosis.

In an international Phase III randomized study, everolimus combined with the hormonal therapy exemestane has dramatically improved progression-free survival for women with metastatic breast cancer.

Partial breast irradiation brachytherapy, an increasingly popular treatment choice for women with early-stage breast cancer, may not be the answer for everyone, according to MD Anderson researchers.

Resources: Frontline

Care to Comment?

Email the editor to comment on a story or offer suggestions on topics you'd like to see covered in future issues of Conquest and Annual Report.

Make a difference

Your gift to MD Anderson makes a difference in the lives of cancer patients by supporting innovative patient care, research, education and prevention programs. You can Donate Now or learn more at myGiving to MD Anderson.

© 2015 The University of Texas MD Anderson Cancer Center